3h agoSeeking AlphaNEUTRAL 50Earnings
Rigel Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-06. The following slide deck was published by Rigel Pharmaceuticals, Inc.
Why Is RIGEL PHARMACEUTICAL Equity (RIGL) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 9 wire stories
RIGEL PHARMACEUTICAL Equity (RIGL) is drawing unusual attention today. Our newswire has captured 9 stories on RIGL across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for RIGL publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
RIGL by the numbers
Coverage: 9 stories / 6 sourcesAI sentiment: 52/100 (mixed)
The headlines behind the move
3h agoThe Motley FoolBULLISH 63Earnings
Rigel (RIGL) Q3 2026 Earnings Call Transcript
VEPPANU launch lifts sales while R289 advances toward 2027 trials.
5h agoSeeking AlphaBULLISH 58Earnings
Rigel outlines $290M-$295M 2026 revenue outlook as VEPPANU launch starts with $6.6M sales
5h agoSeeking AlphaNEUTRAL 50Earnings
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call November 5, 2026 4:30 PM ESTCompany ParticipantsRaymond Furey - Executive VP, Chief Compliance...
12h agoBusiness InsiderBEARISH 44Earnings
Rigel Pharmaceuticals GAAP EPS of $0.70 misses by $0.18, revenue of $80.9M beats by $0.8M
Rigel Pharmaceuticals press release (RIGL): Q3 GAAP EPS of $0.70 misses by $0.18. Revenue of $80.9M (+16.5% Y/Y) beats by $0.8M. Updated 2026 Outlook: Total rev
12h agoThe FlyBULLISH 58Earnings
Rigel Pharmaceuticals narrows 2026 revenue view to $290M-$295M from $285M-$295M
12h agoThe FlyBEARISH 34Earnings
Rigel Pharmaceuticals reports Q3 EPS 65c, consensus 96c
12h agoSEC 8-KNEUTRAL 50General
RIGEL PHARMACEUTICALS INC (RIGL) files 8-K
Filed: 2026-11-05 AccNo: 0001034842-26-000062 Size: 302 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
12h agoPR NewswireBULLISH 64Earnings
Rigel Reports Third Quarter 2026 Financial Results
Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million VEPPANU™ (vepdegestrant) became commercially available in mid-August and generated $6.6 million in...
Frequently asked questions
Why is RIGL stock moving today?
RIGEL PHARMACEUTICAL Equity (RIGL) is drawing unusual attention today. Our newswire has captured 9 stories on RIGL across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "Rigel Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation" (Seeking Alpha).
Is RIGL a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RIGL coverage reads 52/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is CDLR down today (-71.36%)
- Why is VCYT down today (-54.30%)
- Why is APP up today (+31.04%)
- Why is TRIP down today (-27.65%)
- Why is ROCK down today (-27.28%)
- Why is FSLY down today (-26.88%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RIGL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.